From: Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
Patients | Data type | File | Table |
---|---|---|---|
Primary patient cohort | Proteomics | syn22130778 | syn22172602 |
Patients with Sorafenib treatment | Proteomics | syn22313435 | syn22314121 |
Patients with drug combination | Proteomics | syn25672089 | syn22156810 |
Primary patient cohort | Phosphoproteomics | syn24610481 | syn24227903 |
Patients with Sorafenib treatment | Phosphoproteomics | syn24227680 | syn24228075 |
Patients with drug combination | Phosphoproteomics | syn24240156 | syn24240355 |